Dr. Reddy's Laboratories Ltd. NSE: DRREDDY | BSE: 500124

Turnaround Potential

Download real time

1321.70 -1.00 (-0.08%)

29.58% Gain from 52W Low

1.5M

NSE+BSE Volume

NSE 19 Sep, 2025 3:31 PM (IST)

Dr. Reddy's Laboratories Ltd. share price target

Dr. Reddy's Laboratories Ltd. has an average share price target of 1278.56. The consensus estimate represents a downside of -3.26% from the last price of 1321.70. View 18 reports from 9 analysts offering long-term price targets for Dr. Reddy's Laboratories Ltd..

Reco - This broker has downgraded this stock from it's previous report.
(eg. - Buy->Hold)

Target - Broker has maintained previous recommendation but reduced share price target.

Reco - This broker has upgraded this stock from it's previous report.
(eg. - Sell->Hold)

Target - Broker has maintained previous recommendation but increased share price target.

Load latest Google or static link led you to an intermediate page.

Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report		Discuss
	21 Sep 2025	Dr. Reddy's Labs	Consensus Share Price Target	1321.70	1285.13	-	-2.77	hold	pdf Detailed Estimates
	01 Nov 2022	Dr. Reddy's Labs	Axis Direct Target	1321.70	5000.00	4535.30 (-70.86%)	Target met	Buy	pdf post cache		Broker Report Result Update:Dr Reddys Labs Axis Direct We recommend a BUY rating on the stock with a TP of Rs 5,000/share. pdf Copy Link Share on Share on Share on Share on Alert
	31 Oct 2022	Dr. Reddy's Labs	Prabhudas Lilladhar Target	1321.70	4900.00	4535.30 (-70.86%)	Target met	Buy	pdf post cache		Broker Report DR REDDY'S LABS Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	31 Oct 2022	Dr. Reddy's Labs	ICICI Securities Limited Target	1321.70	5134.00	4459.95 (-70.37%)	Target met	Buy	pdf post cache		Broker Report Revlimid springs surprise; outlook intact ICICI Securities Limited Dr. Reddy’s Laboratories’ (DRL) Q2FY23 reported performance exceeded our and consensus estimates, largely driven by strong sales of Revlimid and recovery of US base and Russia sales. pdf Copy Link Share on Share on Share on Share on Alert
	31 Oct 2022	Dr. Reddy's Labs	SMC online	1321.70		4555.65 (-70.99%)	Pre-Bonus/ Split	Results Update	pdf post cache		Broker Report Dr Reddys Laboratories SMC online pdf Copy Link Share on Share on Share on Share on Alert
	29 Oct 2022	Dr. Reddy's Labs	Motilal Oswal Target	1321.70	5180.00	4433.70 (-70.19%)	Target met	Buy	pdf post cache		Broker Report Russia recovers, while PSAI still a drag on earnings Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	29 Oct 2022	Dr. Reddy's Labs	BOB Capital Markets Ltd.	1321.70		4433.70 (-70.19%)	Pre-Bonus/ Split	Hold	pdf post cache		Broker Report Dr Reddy's Labs (HOLD): US launch of gRevlimid buoys quarter BOB Capital Markets Ltd. Q2 revenue up 9% YoY on sales of gRevlimid in the US; gross margin expansion aids EBITDA growth of 42% YoY pdf Copy Link Share on Share on Share on Share on Alert
	29 Oct 2022	Dr. Reddy's Labs	ICICI Direct Target	1321.70	5215.00	4459.95 (-70.37%)	Target met	Buy	pdf post cache		Broker Report Dr Reddy's Laboratories ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	01 Aug 2022	Dr. Reddy's Labs	SMC online	1321.70		4096.30 (-67.73%)	Pre-Bonus/ Split	Results Update	pdf post cache		Broker Report Dr. Reddy`s Laboratories SMC online pdf Copy Link Share on Share on Share on Share on Alert
	29 Jul 2022	Dr. Reddy's Labs	ICICI Direct Target	1321.70	4750.00	4090.35 (-67.69%)	Target met	Buy	pdf post cache		Broker Report Dr Reddy's Laboratories ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	29 Jul 2022	Dr. Reddy's Labs	Prabhudas Lilladhar Target	1321.70	4750.00	4110.45 (-67.85%)	Target met	Buy	pdf post cache		Broker Report DR REDDY'S LABS Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
more loading

* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.

Advisor Screeners